In one quick announcement Monday, Merck's ($MRK) diabetes drug Januvia became the drug to beat in its class. New study data could boost Januvia's sales by 10% in 2020 ...

NEW YORK, Oct 17 (Reuters) - Merck & Co said on Wednesday U.S. regulators have approved use of its Januvia diabetes drug in new combinations with other treatments, but noted reports of serious ...

(Reuters) - Details of a large heart safety study presented on Monday appear to give Merck and Co's diabetes drug Januvia a clean bill of health, possibly setting the stage for a return to sales ...

The long-awaited results, presented Monday at the 75th Scientific Sessions of the American Diabetes Association, are expected to strengthen sitagliptin's position against its competitors in the DPP-4 ...

Positive Opinion For Type 2 Diabetes Treatment, JANUVIA - First In New Class Of Oral Treatments Known As DPP-4 Inhibitors, European Union JANUVIA (sitagliptin), Merck, Sharp & Dohme's treatment for ...

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)-- In a new post-hoc analysis presented for the first time at the American Diabetes Association (ADA) 70 th Annual Scientific Sessions, significantly more ...

With diabetes rivals coming up with heart-helping outcomes data, Merck at least wants data on its label showing its Januvia doesn’t hurt heart health. U.S. regulators, though, say not so fast. Friday, ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio The DPP-IV inhibitor Januvia does not ...

Amylin Pharmaceuticals and Eli Lilly today said their diabetes drug Byetta worked better at reducing blood-sugar levels following a meal compared with Merck's Januvia. The results, based on a a ...

MUNICH -- For type 2 diabetes patients uncontrolled on metformin and sitagliptin (Januvia), adding the novel sodium/glucose cotransporter 2 (SGLT2) inhibitor ertugliflozin improved glycemic levels, a ...

The cardiovascular effects of drugs used for glucose control in patients with diabetes have been a subject of controversy for many years now. More recently, attention has started to focus specifically ...